Filing 2018 Q3 - Restatement compared to 2018 Q2 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Sai Aanandha Shankhar
Senior Advisor
Oslo, Norway
02 Dec 2019
This filing lists securities holdings reported on the Form 13F filed on 11-09-2018 pursuant to a request for confidential treatment for which confidential treatment expired on 11-15-2019. This filing is a restatement of Amendment 1 (filed on 11-12-2019) and Amendment 2 (filed on 12-02-2019) of the Form 13F report for the quarter ended 09-30-2018. The sole change is the date of the original Form 13F filing, included in the legend provided at the top of the Cover Page of Amendment 1 (and not included in Amendment 2), indicating that the confidential treatment period for the filing has expired.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.